Antisoma To Discontinue Phase II Trial Of AS1402

Antisoma has reported that the phase II trial of AS1402 in breast cancer is to be discontinued. This follows a meeting of the trial’s Data Monitoring Committee (DMC) and a subsequent review of the data, which led the company to conclude that the trial would be very unlikely to give sufficient positive efficacy findings. No safety concerns were identified, said the company.

Reportedly, the company has no plans for further studies of AS1402, a humanised antibody against a form of MUC1 found on the surface of various cancers.

The study was a 110-patient phase II trial in women receiving first-line treatment for advanced breast cancer. Patients were randomised to receive either AS1402 plus the hormone therapy letrozole or letrozole alone.